Amy Broidrick - Qualigen Therapeutics Chief Pres
| QLGN Stock | USD 4.47 0.31 6.49% |
Insider
Amy Broidrick is Chief Pres of Qualigen Therapeutics
| Age | 66 |
| Address | 5857 Owens Avenue, Carlsbad, CA, United States, 92008 |
| Phone | 760 452 8111 |
| Web | https://www.qlgntx.com |
Qualigen Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.7507) % which means that it has lost $0.7507 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (8.4166) %, meaning that it created substantial loss on money invested by shareholders. Qualigen Therapeutics' management efficiency ratios could be used to measure how well Qualigen Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Qualigen Therapeutics' Return On Capital Employed is very stable compared to the past year. As of the 27th of November 2024, Return On Equity is likely to grow to 6.70, though Return On Tangible Assets are likely to grow to (6.27). At this time, Qualigen Therapeutics' Non Currrent Assets Other are very stable compared to the past year. As of the 27th of November 2024, Other Current Assets is likely to grow to about 1.4 M, while Total Assets are likely to drop about 1.9 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| AO FRACP | Assembly Biosciences | 65 | |
| Jeffrey PharmD | Nutriband | 54 | |
| Melissa Tosca | Kiora Pharmaceuticals | N/A | |
| Nandan BS | Immix Biopharma | 62 | |
| Boyan MD | Indaptus Therapeutics | 57 | |
| JD MBA | Immix Biopharma | N/A | |
| Tomasz George | Virax Biolabs Group | 40 | |
| Miranda MBA | Entera Bio | 47 | |
| Gerald Goodman | Nutriband | 76 | |
| James Foster | Virax Biolabs Group | 39 | |
| Jason Assad | 180 Life Sciences | N/A | |
| Quan Vu | 180 Life Sciences | 52 | |
| Uri MD | Assembly Biosciences | 52 | |
| Chester III | Revelation Biosciences | 44 | |
| MBA MD | Immix Biopharma | 49 | |
| Michael Newman | Indaptus Therapeutics | 68 | |
| MD MBA | Kiora Pharmaceuticals | 50 | |
| James Rolke | Revelation Biosciences | 55 | |
| MHROD SHRMSCP | Assembly Biosciences | N/A | |
| Cameron Shaw | Virax Biolabs Group | 37 | |
| Jonathan Rothbard | 180 Life Sciences | 71 | |
Management Performance
| Return On Equity | -8.42 | ||||
| Return On Asset | -0.75 |
Qualigen Therapeutics Leadership Team
Elected by the shareholders, the Qualigen Therapeutics' board of directors comprises two types of representatives: Qualigen Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Qualigen. The board's role is to monitor Qualigen Therapeutics' management team and ensure that shareholders' interests are well served. Qualigen Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Qualigen Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| MD MBA, Senior Officer | ||
| Campbell Becher, President Director | ||
| Christopher Lotz, VP Secretary | ||
| Amy Broidrick, Chief Pres | ||
| Robert Becher, President Director | ||
| Michael Poirier, COO, President | ||
| Wajdi AbdulAhad, VP Officer | ||
| Kevin II, Interim CEO | ||
| Shishir Sinha, Corp COO |
Qualigen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Qualigen Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -8.42 | ||||
| Return On Asset | -0.75 | ||||
| Current Valuation | 4.34 M | ||||
| Shares Outstanding | 736.43 K | ||||
| Shares Owned By Insiders | 3.77 % | ||||
| Shares Owned By Institutions | 1.77 % | ||||
| Number Of Shares Shorted | 779.44 K | ||||
| Price To Book | 0.41 X | ||||
| Price To Sales | 0.39 X | ||||
| Revenue | 5.2 M |
Pair Trading with Qualigen Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Qualigen Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Qualigen Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Qualigen Stock
| 0.65 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.83 | JNJ | Johnson Johnson Sell-off Trend | PairCorr |
| 0.9 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
Moving against Qualigen Stock
| 0.83 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
| 0.8 | NAMS | NewAmsterdam Pharma | PairCorr |
| 0.63 | PMVP | Pmv Pharmaceuticals | PairCorr |
| 0.61 | PHVS | Pharvaris BV | PairCorr |
| 0.43 | LPTX | Leap Therapeutics | PairCorr |
The ability to find closely correlated positions to Qualigen Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Qualigen Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Qualigen Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Qualigen Therapeutics to buy it.
The correlation of Qualigen Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Qualigen Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Qualigen Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Qualigen Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Qualigen Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Qualigen Stock, please use our How to Invest in Qualigen Therapeutics guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Qualigen Therapeutics. If investors know Qualigen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Qualigen Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 3.6 K | Revenue Per Share 1.034 | Quarterly Revenue Growth 0.137 | Return On Assets (0.75) | Return On Equity (8.42) |
The market value of Qualigen Therapeutics is measured differently than its book value, which is the value of Qualigen that is recorded on the company's balance sheet. Investors also form their own opinion of Qualigen Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Qualigen Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Qualigen Therapeutics' market value can be influenced by many factors that don't directly affect Qualigen Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Qualigen Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Qualigen Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Qualigen Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.